Crohn’s disease (CD) is a chronic inflammatory bowel disease.1 Despite advances in the management of CD, a significant proportion of patients do not achieve acceptable disease control with conventional therapies, such as corticosteroids, immunomodulators, and anti-tumour necrosis factor (TNF) agents.2-4 Anti-TNF agents, such as infliximab and adalimumab, have become a cornerstone of CD treatment, and have demonstrated significant efficacy in both inducing the remission and its maintenance in patients with moderate to severe CD.5,6. This evidence concerns the gene TNF and Crohn disease.